Interest of S100B Protein for Patient Victim of Minor Traumatic Brain Injury and Treated by Antiplatelet
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Poitiers University Hospital
- Enrollment
- 720
- Locations
- 4
- Primary Endpoint
- Brain scanner Detection of a cerebral lesion requiring a surgery or medical intervention or an hospitalisation for a patient who have serum level of S100B protein with the treshold of 0.105 μg/L
Study Overview
Brief Summary
All the patients admitted in emergency department for minor traumatized cranial, with antiplatelet therapy, can be included, after checked inclusion and non inclusions criterias. If they are agree, a blood sample for the dosage of S100b will be done.
No other modification of the medical care, all patients will have tomodensitometria, according with recommendations. The aim of the study is to validate the negative predictive value of S100b in this population.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Diagnostic
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age > 18 Years old
- •Minor traumatic brain injury measured by a Glasgow score between 13 and 15
- •Antiplatelet agent therapy
- •Free subject without tutorship or curatorship
Exclusion Criteria
- •Age < 18 years old
- •Glasgow score <13
- •Traumatic brain injury older than 6 hours
- •Patient without any social security system
- •Patient with renforced protection (tutorship, curatorship, …)
Arms & Interventions
S100B protein dosing
Intervention: S100B protein dosing (Biological)
Outcomes
Primary Outcomes
Brain scanner Detection of a cerebral lesion requiring a surgery or medical intervention or an hospitalisation for a patient who have serum level of S100B protein with the treshold of 0.105 μg/L
Time Frame: 3 hours
Secondary Outcomes
No secondary outcomes reported